Skip to main content
AUPH
NASDAQ Life Sciences

Aurinia Pharmaceuticals Reports Strong Q1 2026 Results with 24% Revenue Growth and 56% EPS Increase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.3
Mkt Cap
$2.16B
52W Low
$7.285
52W High
$16.88
52W Position info
124% above low
Off High info
3.4% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AUPH has more than doubled off its 52-week low of $7.285.

Summary

Aurinia Pharmaceuticals announced strong first-quarter 2026 financial results, including significant revenue and EPS growth, exceptional operating cash flow, and reiterated full-year guidance.


Key Events · Earnings and Guidance · AUPH

  • Strong Q1 2026 Financial Performance

    Total revenue increased 24% to $77.7 million, with net income up 48% to $34.4 million and diluted EPS rising 56% to $0.25 compared to Q1 2025.

  • Significant LUPKYNIS Sales Growth

    Net product sales of LUPKYNIS grew 23% to $73.6 million for the quarter, highlighting continued market penetration for its key therapy.

  • Exceptional Operating Cash Flow

    Cash flows from operating activities reached $32.6 million, a remarkable 2408% increase from $1.3 million in the same period last year.

  • Reiterated Full-Year Guidance

    Aurinia reaffirmed its 2026 total revenue guidance of $315 million to $325 million and net product sales guidance of $305 million to $315 million, projecting 11-16% growth over 2025.


Analysis · AUPH · Life Sciences

Aurinia Pharmaceuticals delivered a robust first quarter, showcasing significant growth across key financial metrics. Total revenue increased by 24% year-over-year, driven by a 23% rise in net product sales of LUPKYNIS. The company also achieved a substantial 48% increase in net income and a 56% jump in diluted earnings per share. Notably, cash flows from operating activities surged by an exceptional 2408% compared to the prior year, demonstrating strong operational efficiency and cash generation. The company reiterated its full-year 2026 revenue and net product sales guidance, signaling confidence in its continued performance. These strong results provide fundamental support for the stock, which is currently trading near its 52-week high, and reinforce the positive financial turnaround reported in the previous 10-K.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AUPH was trading at $16.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AUPH - Latest Insights

AUPH
Oct 30, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.62
Real-time Price: $14.64 info
Change: -$1.98 (-12%) info
Market Cap: $1.97B info
AUPH
Oct 30, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $17.21
Real-time Price: $14.64 info
Change: -$2.57 (-15%) info
Market Cap: $1.97B info
AUPH
Aug 19, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.34
Real-time Price: $14.64 info
Change: -$1.70 (-10%) info
Market Cap: $1.97B info
AUPH
Aug 19, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.57
Real-time Price: $14.64 info
Change: -$1.93 (-12%) info
Market Cap: $1.97B info
AUPH
Aug 06, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $14.64 info
Change: -$1.11 (-7%) info
Market Cap: $1.97B info